Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndrome With Excess Blasts: early-phase trial registry
5 of 9 indexed Myelodysplastic Syndrome With Excess Blasts trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Myelodysplastic Syndrome With Excess Blasts: 9 US clinical trials tracked, 5 recruiting.
Myelodysplastic Syndrome With Excess Blasts is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndrome-with-excess-blasts
OPEN 5 | RECR 56% | LATE 0 | EARLY 9 | RANK #1916 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)
Myelodysplastic Syndrome With Excess Blasts lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndrome With Excess Blasts on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndrome With Excess Blasts is recruiting above its size-band peers.
5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myelodysplastic Syndrome With Excess Blasts research.
National Cancer Institute (NCI) accounts for 4 of 9 trials (44.4%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Myelodysplastic Syndrome With Excess Blasts enrolment sits around 75 participants.
Median target enrolment is 75 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.
-
Myelodysplastic Syndrome With Excess Blasts research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00801489
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT03128034
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03383575
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
NCT03816319
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03670966
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT01522976
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT00392353
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
NCT05600894
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT03399773
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndrome With Excess Blasts records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndrome With Excess Blasts trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndrome With Excess Blasts page
9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Myelodysplastic Syndrome With Excess Blasts trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Myelodysplastic Syndrome With Excess Blasts trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndrome With Excess Blasts condition card totals 9 registered trials; most-linked intervention Azacitidine; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.